Vemurafenib
About
Therapy type: Targeted therapy
Therapy strategy: B-RAF inhibition
Mappings
NCI Thesaurus: Vemurafenib (ncit:C64768)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRAF p.V600E | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | FDA |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | FDA |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Cobimetinib, Vemurafenib | FDA |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib | FDA |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Vemurafenib | FDA |
| Sensitivity (+) | BRAF p.V600E | Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease | Vemurafenib | FDA |
| Sensitivity (+) | BRAF p.V600K | Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease | Vemurafenib | FDA |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Cobimetinib, Vemurafenib | HC |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib | HC |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Vemurafenib | HC |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Vemurafenib | HC |